Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid Population, 1998-2003

Clinical Therapeutics

Volumn 29, Issue 1, 2007, Pages 183-195

  Morrato, Elaine H ^a   Dodd, Sheri ^b   Oderda, Gary ^c   Haxby, Dean G ^d   Allen, Richard ^e   Valuck, Robert J ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Department of Pharmacy Practice   (United States)

^e Peak Statistical Services   (United States)

Author keywords

antipsychotic agents; drug use review; Medicaid; mentally ill persons

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MENTAL DISEASE; MENTAL HEALTH CARE; MONOTHERAPY; POLYPHARMACY; PREDICTION; PREVALENCE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICAID; MENTAL DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYPHARMACY; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS;

EID: 33947273551     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.01.002     Document Type: Article

References (23)

1. Stahl S.M. Antipsychotic polypharmacy: Evidence based or eminence based?. Acta Psychiatr Scand 106 (2002) 321-322
2. Sernyak M.J., and Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 65 (2004) 1597-1600
3. Stahl S.M., and Grady M.M. A critical review of atypical antipsychotic utilization: Comparing monotherapy with polpharmacy and augmentation. Curr Med Chem. 11 (2004) 313-327
4. Centorrino F., Goren J.L., Hennen J., et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 161 (2004) 700-706
5. Rosenheck R., Leslie D., and Sernyak M. From clinical trials to real-world practice: Use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care 39 (2001) 302-308
6. Zuvekas S.H. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Alf (Millwood) 24 (2005) 195-205
7. Stahl S.M., and Grady M.M. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 57 (2006) 127-129
8. Leslie D.L., and Rosenheck R.A. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: Individual and facility predictors. Med Care 39 (2001) 923-933
9. Ganguly R., Kotzan J.A., Miller L.S., et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65 (2004) 1377-1388
10. Faries D., Ascher-Svanum H., Zhu B., et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5 (2005) 26
11. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 60 Suppl 10 (1999) 20-30
12. Patrick V., Schleifer S.J., Nurenberg J.R., and Gill K.J. Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 57 (2006) 21-23
13. Kogut S.J., Yam F., and Dufresne R. Prescribing of antipsychotic medication in a Medicaid population: Use of polytherapy and off-label dosages. J Manag Care Pharm 11 (2005) 17-24
14. State Medicaid Fact Sheet 2. Available at: http://www.kff.org/mfs/ index.jsp. Accessed May 16, 2006.
15. Lehman A.F., Lieberman J.A., Dixon L.B., et al., American Psychiatric Association, Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 Suppl 2 (2004) 1-56
16. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry 60 Suppl 11 (1999) 3-80
17. discussion 575-577. Andrade S.E., Kahler K.H., Frech F., and Chan K.A. Methods for evaluation of medication adherence and persis tence using automated databases. Pharmacoepidemiol Drug Saf 15 (2006) 565-574
18. Bromet E.J., Dew M.A., and Eaton W.W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang M., Tohen M., and Zahner G. (Eds). Textbook in Psychiatric Epidemiology. 2nd ed. (2002), Wiley-Liss, Inc, New York, NY 363-387
19. Ananth J., Parameswaran S., and Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Des 10 (2004) 2231-2238
20. Kressin N.R., Chang B.H., Hendricks A., and Kazis L.E. Agreement between administrative data and patients' self reports of race/ethnicity. Am J Public Health 93 (2003) 1734-1739
21. McBean A.M. Improving Medicare's data on race and ethnicity. Medicare Brief 15 (2006) 1-7
22. Pan C.X., Glynn R.J., Mogun H., et al. Definition of race and ethnicity in older people in Medicare and Medicaid. J Am Geriatr Soc 47 (1999) 730-733
23. Guide to Medi-Cal Trend Report for FY 1998-99 through FY 2002-03. Available at: http://www.dmh.ca.gov/ SADA/SDA-Medi-Cal.asp. Accessed May 16, 2006.